Brian More, CEO of Nanovis, on Nanotechnology, Focused Execution, and Strategic Growth

We sit down with Brian More, CEO of Nanovis, for a candid conversation on strategy, science, and scaling up smart. From startup grit to a groundbreaking collaboration with Medtronic, Brian shares how Nanovis is transforming orthopedic and spinal implants through surface-level innovation, and why staying focused is the key to long-term success.

AI for Stroke: A Conversation with Brad Wittenberg from Brainomix

Founded as a spin-out from the University of Oxford, Brainomix has already transformed stroke care across Europe. With more than 70% market share in the UK and over 60 peer-reviewed publications validating its efficacy in real world settings, the company has delivered what few others can: evidence-based, scalable AI that improves outcomes and makes stroke systems more efficient.

Monica Burt on Why Most MedTech Companies Are Doing Quality All Wrong—and How to Fix It Before It Breaks You

“We often joke that we’re the Green Berets of quality,” says Monica Burt, founder of MB&A. “When things go sideways—an FDA audit is imminent, a system is unraveling, or a product launch is on life support—we get the call.”In this candid conversation with The MedTech Digest, Monica Burt pulls back the curtain on why most MedTech companies are doing quality all wrong—and how her team is helping them fix it before it breaks them. From debunking the myth that more paperwork equals more compliance, to rebuilding systems that actually enable innovation, Burt’s insights are equal parts sharp, strategic, and human.

Tariff Talks: One-on-One with Tim Sheehan, BlackPoint Capital Markets, Managing Director – Episode 1, Part 2

MedTech companies from both sides of the Atlantic kept reaching out to us since the beginning of the year, worried about what was happening in the U.S. with the new administration and how it might affect their business. They wanted guidance, insights, and most importantly, an educated path forward.

Tariff Talks: One-on-One with Tim Sheehan, BlackPoint Capital Markets, Managing Director – Episode 1, Part 1

MedTech companies from both sides of the Atlantic kept reaching out to us since the beginning of the year, worried about what was happening in the U.S. with the new administration and how it might affect their business. They wanted guidance, insights, and most importantly, an educated path forward.

Cody Simmons

Exclusive Interview: A Look Inside DermaSensor’s Journey to Innovation with CEO, Cody Simmons

I’ve learned and shared with people that whenever you have a major setback – whether study-related, study timeline change or product setback and timeline change, just reevaluate your whole approach and strategy because even with your well-laid plans, when one of the pieces of the plan changes, you realize other doors could open.

  • 1
  • 2